| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Levin Andrew David | Director | C/O VOR BIOPHARMA INC., 500 BOYLSTON STREET, SUITE 1350, BOSTON | /s/ Adi Osovsky, Attorney-in-Fact | 19 Dec 2025 | 0001867539 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VOR | Stock Option (Right to Buy) | Award | $0 | +3,000 | $0.000000 | 3,000 | 18 Dec 2025 | Common Stock | 3,000 | $12.80 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date. |
| F2 | Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. |